China’s new commercial insurance model could broaden access to Alzheimer’s drugs
China’s new commercial insurance formulary looks to expand patient access to Alzheimer’s disease medicines from Eli Lilly and…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Eli Lilly Scores Another Major Win: Time to Buy?
Eli Lilly’s next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump
24/7 Wall St. Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal
Shelby Knowles / Bloomberg / Getty Images Eli Lilly shares have added over a third of their value…
Seasoned Healthcare Executive Raises $52 Million For An AI Health Startup
Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like…
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will…